Heprest 300 Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid used primarily in the management of cholestatic liver diseases. It is indicated for the treatment of primary biliary cholangitis, where it helps to improve liver function by reducing the cytotoxicity of bile acids and promoting bile flow. Ursodeoxycholic acid acts by decreasing the cholesterol content of bile and dissolving cholesterol gallstones in patients who are not candidates for surgery. Additionally, it has hepatoprotective properties, stabilizing hepatocyte membranes and reducing inflammation and fibrosis in the liver. Heprest 300 is administered orally, with dosage tailored according to the patient’s weight and clinical condition. Common adverse effects are generally mild and may include gastrointestinal disturbances such as diarrhea, nausea, or abdominal discomfort. It is contraindicated in patients with complete biliary obstruction and should be used cautiously in those with advanced liver disease. Regular monitoring of liver function tests is recommended during therapy to assess efficacy and detect potential adverse reactions. Heprest 300 Tablet should be prescribed and used under medical supervision to ensure optimal therapeutic outcomes in hepatic and biliary disorders.